<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556424</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0056</org_study_id>
    <nct_id>NCT02556424</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema</brief_title>
  <acronym>TRIOZ</acronym>
  <official_title>Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticosteroids, whether injected peri- or intra-ocularly, remain indispensable tools of the&#xD;
      therapeutic arsenal in treating inflammatory macular edema. However, a few years ago, only&#xD;
      triamcinolone acetonide was available to ophthalmologists. This molecule, developed initially&#xD;
      for rheumatological or dermatological use, has been increasingly deployed in ophthalmology,&#xD;
      while still off-label.&#xD;
&#xD;
      In 2011, the delivery system of dexamethasone from biodegradable and injectable implant into&#xD;
      the vitreous cavity obtained the label for inflammatory macular edema. This protocol is&#xD;
      therefore designed to compare the efficacy and safety of peri- and intra-ocular injections of&#xD;
      corticosteroids in the treatment of inflammatory macular edema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research compares the implantation techniques of corticosteroids in the eye, with two&#xD;
      groups of equal size being followed. This is a multi-center, controlled study, with the&#xD;
      reference drug being the intravitreal implant of 700μg of dexamethasone (Ozurdex®) compared&#xD;
      to subconjunctival injection of triamcinolone (Kénacort retard®). This is an open,&#xD;
      prospective, randomized study. It is not possible, for technical reasons, to inject blind two&#xD;
      products with different injection routes and that are visible to the investigator during&#xD;
      control examinations (sub-conjunctival crystals and intravitreal implant). However, the&#xD;
      assessment of visual acuity and central macular thickness will be performed by an uninformed&#xD;
      ophthalmologist.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the effectiveness of a subconjunctival injection of triamcinolone on reducing the central macular thickness versus an intravitreal implant of dexamethasone between patient selection and 2 months after treatment</measure>
    <time_frame>At 2 months after treatment</time_frame>
    <description>Difference of the central macular thickness in the treated eye, measured by Optical Coherence Tomography (OCT) spectral domain, for each patient between patient selection and 2 months after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the experience of the injection by a questionnaire (tolerable, unpleasant and very unpleasant) and by EVA (0 cm = no pain to 10 cm = extreme pain)</measure>
    <time_frame>At day 0 (= the day of the treatment)</time_frame>
    <description>Scale of &quot;patient experience&quot; the day of the injection (tolerable, unpleasant, very unpleasant) and visual analogue scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding gain in visual acuity (ETDRS)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Visual acuity (ETDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding reduction of the anterior flare</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Anterior flare (&quot;Lampe A Fente&quot; and Laser Flare Meter, if available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding reduction of the vitreous haze</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Vitreous flare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding central macular thickness measured by OCT, allowing the evaluation of the duration of action of the treatment</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Central macular thickness of the eye treated for determining the duration of action</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding local and general tolerance, by collecting all Adverse Events (AEs) / Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluation of tolerance by collecting all AEs / SAEs of randomized patients, such as intra-ocular hypertension, cataracts, endophthalmitis, poor glycemic and/or blood pressure control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness of the studied injection at each visit regarding patients' quality of life</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Patients' quality of life questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Inflammatory Macular Edema</condition>
  <arm_group>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal implant of 700μg of dexamethasone (Ozurdex®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tested Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intravitreal implant at D0</description>
    <arm_group_label>Reference Drug</arm_group_label>
    <other_name>Ozurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Subconjunctival injection at 4 mm from the limbus at 6 o'clock</description>
    <arm_group_label>Tested Drug</arm_group_label>
    <other_name>Kénacort retard®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient, male or female (under effective contraception if premenopausal) over 18 years&#xD;
             old&#xD;
&#xD;
          -  Patient affiliated with a social security plan&#xD;
&#xD;
          -  Patient able to understand and follow the instructions of the study&#xD;
&#xD;
          -  Patient having signed an informed consent&#xD;
&#xD;
          -  Patient having a central macular thickness greater than 320μm (Spectral Domain, 270µm&#xD;
             Time Domain)&#xD;
&#xD;
          -  Patient with an inflammatory macular edema, unilateral or bilateral (in the case of a&#xD;
             bilateral inflammatory macular edema, the eye most affected will be treated)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with an infectious uveitis&#xD;
&#xD;
          -  Patient with uncontrolled active infection&#xD;
&#xD;
          -  Patient receiving an unbalanced general anti-inflammatory and/or immunosuppressive&#xD;
             and/or immunomodulatory therapy (recent modification &lt;1 month)&#xD;
&#xD;
          -  Patient having a history of glaucoma and/or ocular hypertension in the eye studied&#xD;
             (intraocular pressure (IOP) &gt; 25 mmHg without antiglaucoma medication or &gt; 21 mmHg&#xD;
             with antiglaucoma combination therapy) and/or cortisone-causing-hypertension not&#xD;
             controlled by an antiglaucoma dual therapy&#xD;
&#xD;
          -  Patient with uncontrolled diabetes (HbA1c&gt; 8%) or unbalanced hypertension (Systolic&#xD;
             Blood Pressure &gt; 160 mmHg and/or Diastolic Blood Pressure &gt; 100mmHg)&#xD;
&#xD;
          -  Edematous diabetic maculopathy&#xD;
&#xD;
          -  Patient who had received triamcinolone (subconjunctivally or sub-tenon) 3 months&#xD;
             before randomization, or 700μg dexamethasone intravitreally 6 months before&#xD;
             randomization&#xD;
&#xD;
          -  Suspected or active ocular or periocular infection, including most viral diseases of&#xD;
             the cornea and conjunctiva, such as active epithelial keratitis with herpes simplex&#xD;
             (dendritic keratitis), vaccinia, varicella, mycobacterial infections and mycoses&#xD;
&#xD;
          -  History of ocular herpes infection or central serous chorioretinopathy&#xD;
&#xD;
          -  Aphakic eye with rupture of the posterior lens capsule&#xD;
&#xD;
          -  Eye with implant in the anterior chamber, iris- or transscleral-fixated intraocular&#xD;
             implant and rupture of the posterior lens capsule&#xD;
&#xD;
          -  Uncontrolled systemic inflammatory disease.&#xD;
&#xD;
          -  Known hypersensitivity to the active substance or to one of the excipients of&#xD;
             Ozurdex®, Kenacort® or injectable fluorescein&#xD;
&#xD;
          -  Pregnant woman or likely to become pregnant or nursing&#xD;
&#xD;
          -  Patient participating in another clinical trial&#xD;
&#xD;
          -  Adult under a legal protection regime (guardianship, trusteeship, &quot;sauvegarde de&#xD;
             justice&quot;)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre (AP-HP)</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié-Salpêtrière (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ophthalmology</keyword>
  <keyword>Uveitic macular edema</keyword>
  <keyword>Triamcinolone subconjunctival injection</keyword>
  <keyword>Dexamethasone intraocular implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

